Clinical Outcomes of Patients With Coronary Artery Disease
ConditionCoronary Heart Disease (CHD)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorShenyang Northern Hospital
About this trial
Coronary heart disease (CHD) stands as a foremost contributor to global mortality, characterized by complex pathogenesis that renders conventional "one-size-fits-all" preventive strategies inefficient. Therefore, the investigators designed a prospective, multi-center cohort study among patients hospitalized due to either confirmed or suspected CHD, which aimed to establish a holographic data set for the diagnosis and treatment of CHD and explore the impact of critical therapeutic strategies in the real world on the clinical outcomes of CHD patients, providing evidence to optimize the management pathway.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 years old
Hospitalization due to either confirmed or suspected CHD combined with one of the following features: previous PCI or CABG; previous myocardial infarction; previous coronary angiography revealing ≥ 50% stenosis in major coronary vessels; presentation with chest pain and pre-test probability of CHD > 65%; laboratory tests revealing objective evidence of myocardial ischemia; coronary CT angiography (CTA) showed ≥ 30% stenosis in major coronary vessels
Subjects undergoing at least one coronary imaging and one functional examination. Imaging examinations include coronary CTA, intravascular ultrasound (IVUS), or optical coherence tomography (OCT). Functional examination include fraction flow reservation (FFR), CT-FFR or quantitative flow ratio (QFR).
Written informed consent provided.
Disqualifiers
History of mental illness, drug or alcohol abuse, or being unable to cooperate with follow-up visits for any reason;
Life expectancy <1 year
Pregnant or plan to be pregnant within 1 year
Subjects participating in any other clinical trial
Trial population
patients hospitalized due to either confirmed or suspected CHD
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Ischemic events
defined as the composite of cardiac death, myocardial infarction, or stroke
Time frame
During 12-month follow upSecondary outcomes
1
Major adverse cardiovascular and cerebrovascular events (MACCE)
defined as a composite of all-cause death, myocardial infarction, ischemic stroke and target-vessel revascularization
Time frame
During 1/2/3/4/5-year follow up2
Cardiac death
Time frame
During 1/2/3/4/5-year follow up3
Stent thrombosis
Time frame
During 1/2/3/4/5-year follow up4
Major bleeding events
defined as BARC types 3 or 5 bleeding events
Time frame
During 1/2/3/4/5-year follow upSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov